BioXcel's phase 3 schizophrenia film has blockbuster potenti...

A sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could pose a threat to an inhaled rival from Galen, according to anal

Lundbeck gets cold feet, axes schizophrenia drug trial

Lundbeck has axed a phase 2 trial of a schizophrenia drug, saying that the study was unlikely to meet its efficacy target.

Lundbeck announces plans to cut a fifth of R&D workforce

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department. 

Pear rolls out digital therapy for schizophrenia under FDA’s...

Intra-Cellular ends year with OK for schizophrenia drug luma...

Newron faces delay to would-be schizophrenia blockbuster

Newron has been forced to delay the start of a pivotal trial of its schizophrenia candidate evenamide – tipped as a potential blockbuster – after an FDA query about safety data from animal